BR0015103A - Compostos - Google Patents

Compostos

Info

Publication number
BR0015103A
BR0015103A BR0015103-3A BR0015103A BR0015103A BR 0015103 A BR0015103 A BR 0015103A BR 0015103 A BR0015103 A BR 0015103A BR 0015103 A BR0015103 A BR 0015103A
Authority
BR
Brazil
Prior art keywords
cdr1
cdr2
cdr3
seq
antibody
Prior art date
Application number
BR0015103-3A
Other languages
English (en)
Inventor
Thomas N Brodin
Pia J Karlstrom
Lennart G Ohlsson
M Jesper Tordsson
Phillip P Kearney
Bo H K Nilson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of BR0015103A publication Critical patent/BR0015103A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"COMPOSTOS". Um anticorpo ou derivado ou um fragmento do mesmo tendo uma estrutura de ligação a uma estrutura a alvo é descrito. O anticorpo é visualizado em e sobre a superfície celular de células tumorígenas epiteliais gastrointestinais humanas e em uma subpopulação de células epiteliais gastrointestinais normais humanas. A referida estrutura de ligação compreende as seq³ências da região de determinação de complementariedade (CDR) na cadeia leve compreendendo essencialmente os aminoácidos números 23-33 (CDR1), 49-55 (CDR2), 88-98 (CDR3) da seq³ência de aminoácido mostrada em SEQ ID N<0>2 e as seq³ências de CDR na cadeia pesada compreendendo essencialmente os aminoácidos números 158-162 (CDR1), 177-193 (CDR2), 226-238 (CDR3) da seq³ência de aminoácido mostrada em SEQ ID N<0>2 ou outras estruturas de ligação com propriedades de ligação únicas similares. Também é descrita uma estrutura alvo visualizada em ou sobre a superfície de células tumorígenas, composições de vacina, composições farmacêuticas, bem como métodos relacionados a doenças malignas humanas.
BR0015103-3A 1999-10-28 2000-10-26 Compostos BR0015103A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9903895A SE9903895D0 (sv) 1999-10-28 1999-10-28 Novel compounds
PCT/SE2000/002082 WO2001030854A2 (en) 1999-10-28 2000-10-26 Antibody to human gastrointestinal epithelial tumor antigen related to alpha 6 beta 4 integrin

Publications (1)

Publication Number Publication Date
BR0015103A true BR0015103A (pt) 2002-07-16

Family

ID=20417520

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0015103-3A BR0015103A (pt) 1999-10-28 2000-10-26 Compostos

Country Status (18)

Country Link
US (2) US7189816B1 (pt)
EP (1) EP1232186A2 (pt)
JP (1) JP2003513024A (pt)
KR (1) KR20020047288A (pt)
CN (1) CN1229391C (pt)
AU (1) AU773568B2 (pt)
BR (1) BR0015103A (pt)
CA (1) CA2386926A1 (pt)
EE (1) EE200200224A (pt)
HU (1) HUP0203297A2 (pt)
IL (1) IL149245A0 (pt)
NO (1) NO20021436L (pt)
NZ (1) NZ518300A (pt)
PL (1) PL354508A1 (pt)
RU (1) RU2266298C2 (pt)
SE (1) SE9903895D0 (pt)
WO (1) WO2001030854A2 (pt)
ZA (1) ZA200202221B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102327D0 (sv) 2001-06-28 2001-06-28 Active Biotech Ab A novel engineered superantigen for human therapy
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
WO2007071051A1 (en) * 2005-12-21 2007-06-28 Viventia Biotech Inc. Novel cancer-associated antigen
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
CN101669031A (zh) * 2007-02-27 2010-03-10 森托科隆股份公司 使用与细胞外标记物结合的试剂组多重检测肿瘤细胞
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
CN101874042B9 (zh) * 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
GB0719231D0 (en) 2007-10-03 2007-11-14 Oxford Genome Sciences Uk Ltd Protein
CA2708532C (en) 2007-12-05 2018-06-05 Chugai Seiyaku Kabushiki Kaisha Anti-il31ra antibody and use thereof
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI682995B (zh) 2009-03-19 2020-01-21 日商中外製藥股份有限公司 抗體恆定區域改變體
KR20120024763A (ko) 2009-05-15 2012-03-14 추가이 세이야쿠 가부시키가이샤 항ａｘｌ 항체
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
JP5889181B2 (ja) 2010-03-04 2016-03-22 中外製薬株式会社 抗体定常領域改変体
PH12016502073B1 (en) 2010-11-17 2024-04-05 Chugai Pharmaceutical Co Ltd Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
KR101860280B1 (ko) 2014-12-19 2018-05-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
CN114773470A (zh) 2015-02-05 2022-07-22 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
JP6130983B2 (ja) 2015-02-27 2017-05-17 中外製薬株式会社 Ｉｌ−６関連疾患治療用組成物
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
TN2018000112A1 (en) 2015-10-29 2019-10-04 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5320942A (en) * 1987-02-19 1994-06-14 Vito Quaranta Method of diagnosing the presence of abnormal epithelial tissue using monoclonal antibodies to the A6 B4 cell surface protein
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2078817A1 (en) 1991-10-18 1993-04-19 Beat A. Imhof Anti-.alpha.6-integrin-antibodies
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
AU8691398A (en) * 1997-08-04 1999-02-22 Ixsys, Incorporated Methods for identifying ligand specific binding molecules

Also Published As

Publication number Publication date
EP1232186A2 (en) 2002-08-21
US20070112179A1 (en) 2007-05-17
CN1229391C (zh) 2005-11-30
CA2386926A1 (en) 2001-05-03
US7189816B1 (en) 2007-03-13
NO20021436L (no) 2002-06-19
SE9903895D0 (sv) 1999-10-28
PL354508A1 (en) 2004-01-26
HUP0203297A2 (hu) 2003-01-28
AU1424801A (en) 2001-05-08
AU773568B2 (en) 2004-05-27
WO2001030854A2 (en) 2001-05-03
EE200200224A (et) 2003-06-16
NO20021436D0 (no) 2002-03-22
RU2266298C2 (ru) 2005-12-20
WO2001030854A3 (en) 2001-12-06
JP2003513024A (ja) 2003-04-08
IL149245A0 (en) 2002-12-01
CN1384840A (zh) 2002-12-11
KR20020047288A (ko) 2002-06-21
NZ518300A (en) 2004-03-26
ZA200202221B (en) 2003-05-28

Similar Documents

Publication Publication Date Title
BR0015103A (pt) Compostos
IL129299A0 (en) Monoclonal antibodies antigens and diagnosis of malignant diseases
JP7073487B2 (ja) 操作された抗体化合物およびこれらの抱合体
ES2699312T3 (es) Enlace covalente reversible de moléculas funcionales
ES2494191T3 (es) Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para su utilización en tratamientos
RU2015116485A (ru) Антитела к рецептору альфа 2 интерлейкина-13 и конъюгаты антитело-лекарственное средство
ES2494190T3 (es) Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje proteico sin Ig anti-ADM para reducir el riesgo de mortalidad en un paciente que padece una enfermedad crónica o aguda o un estado agudo
BRPI0516284A (pt) anticorpo construìdo com cisteìna, método de selecionar anticorpos, compostos conjugados de droga-anticorpo, composição farmacêutica, método para matar ou inibir a proliferação de células de tumor, métodos de inibir a proliferação celular e o crescimento de células de tumor, artigo manufaturado e método para produzir um composto
BRPI0314038B8 (pt) anticorpo humano isolado, molécula de ácido nucleico isolada, vetor, uso de um anticorpo, e, composição farmacêutica
ES2879815T3 (es) Anticuerpos que se unen a los aminoácidos 13-27 de PIVKA-II
JP2016503295A5 (pt)
BRPI0510883A (pt) composto conjugado de droga e anticorpo, composição farmacêutica, métodos de inibição da proliferação celular, de tratamento de cáncer, de inibição do crescimento de células tumorosas e de tratamento de paciente humano suscetìvel à disfunção, teste de detecção de células cancerosas, artigo industrializado e método de fabricação de composto conjugado de droga e anticorpo
RU2002113741A (ru) Антитела к антигену эпителиальных опухолей желудочно-кишечного тракта человека, родственному альфа 6 бета 4 интегрину
NZ575245A (en) Targeted binding agents directed to pdgfr-alpha and uses thereof
HRP20141111T1 (hr) Sastav her2-protutijela
CY1113370T1 (el) Ενεσιμο φαρμακευτικο σκευασμα αποτελουμενο απο ενα κυτταροστατικο και μια μηλεϊνιμιδο ομαδα συνδεομενη δια ενος παρεμβαλλομενου μοριου
RU2010116152A (ru) Антитело против рецептора il-6
AU2012315792A1 (en) Therapeutic peptides
WO2018033749A1 (en) Anti-psma antibodies, uses thereof and conjugates thereof
CY1108898T1 (el) Προϊοντα συζευξης πεπτιδιων και πεπτιδομιμητικων ενωσεων με ιδιοτητες αναστολεα ενσωματινης
RU2011130522A (ru) Моноклональное антитело против hcv в качестве лекарственного средства для терапевтического лечения и профилактики инфекций hcv
EP1667716B8 (en) Cytotoxicity mediation of cells evidencing surface expression of cd44
CY1106644T1 (el) Ρυθμιστικα/αναδιπλωμενα πεπτιδια της εζρινης
DE4402756A1 (de) Spezifische Bindungssubstanzen für Antikörper und deren Verwendung für Immunoassays oder Vakzine
CN113667011A (zh) 制备抗原结合单元的方法

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A E 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.